IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1d10.1007_s10198-014-0591-7.html
   My bibliography  Save this article

Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries

Author

Listed:
  • László Gulácsi

    (Corvinus University of Budapest)

  • Fanni Rencz

    (Corvinus University of Budapest
    Semmelweis University)

  • Márta Péntek

    (Corvinus University of Budapest
    Flór Ferenc County Hospital)

  • Valentin Brodszky

    (Corvinus University of Budapest)

  • Ruth Lopert

    (George Washington University
    LW Health Policy Consulting)

  • Noémi V. Hevér

    (Corvinus University of Budapest)

  • Petra Baji

    (Corvinus University of Budapest)

Abstract

Background Several Central and Eastern European (CEE) countries require cost-utility analyses (CUAs) to support reimbursement formulary listing. However, CUAs informed by local evidence are often unavailable, and the cost-effectiveness of the several currently reimbursed biologicals is unclear. Aim To estimate the cost-effectiveness as multiples of per capita GDP/quality adjusted life years (QALY) of four biologicals (infliximab, etanercept, adalimumab, golimumab) currently reimbursed in six CEE countries in six inflammatory rheumatoid and bowel disease conditions. Methods Systematic literature review of published cost-utility analyses in the selected conditions, using the United Kingdom (UK) as reference country and with study selection criteria set to optimize the transfer of results to the CEEs. Prices in each CEE country were pro-rated against UK prices using purchasing power parity (PPP)-adjusted per capita GDP, and local GDP per capita/QALY ratios estimated. Results Central and Eastern European countries list prices were 144–333 % higher than pro rata prices. Out of 85 CUAs identified by previous systematic literature reviews, 15 were selected as a convenience sample for estimating the cost-effectiveness of biologicals in the CEE countries in terms of per capita GDP/QALY. Per capita GDP/QALY values varied from 0.42 to 6.4 across countries and conditions (Bulgaria: 0.97–6.38; Czech Republic: 0.42–2.76; Hungary: 0.54–3.54; Poland: 0.59–3.90; Romania: 0.77–5.07; Slovakia: 0.55–3.61). Conclusion While results must be interpreted with caution, calculating pro rata (cost-effective) prices and per capita GDP/QALY ratios based on CUAs can aid reimbursement decision-making in the absence of analyses using local data.

Suggested Citation

  • László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi V. Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0591-7
    DOI: 10.1007/s10198-014-0591-7
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-014-0591-7
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-014-0591-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Cécile Gaujoux-Viala & Bruno Fautrel, 2012. "Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis," PharmacoEconomics, Springer, vol. 30(12), pages 1145-1156, December.
    2. Imre Boncz & Júlia Nagy & Andor Sebestyén & László Kőrösi, 2004. "Financing of health care services in Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 5(3), pages 252-258, September.
    3. Huiqin Yang & Dawn Craig & David Epstein & Laura Bojke & Kate Light & Ian Bruce & Mark Sculpher & Nerys Woolacott, 2012. "Golimumab for the Treatment of Psoriatic Arthritis," PharmacoEconomics, Springer, vol. 30(4), pages 257-270, April.
    4. L. Gulácsi & E. Orlewska & M. Péntek, 2012. "Health economics and health technology assessment in Central and Eastern Europe: a dose of reality," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(5), pages 525-531, October.
    5. Cécile Gaujoux-Viala & Bruno Fautrel, 2012. "Cost Effectiveness of Therapeutic Interventions in Ankylosing Spondylitis," PharmacoEconomics, Springer, vol. 30(12), pages 1145-1156, December.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. László Gulácsi & Fanni Rencz & Márta Péntek & Valentin Brodszky & Ruth Lopert & Noémi Hevér & Petra Baji, 2014. "Transferability of results of cost utility analyses for biologicals in inflammatory conditions for Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 27-34, May.
    2. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    3. Márta Péntek & Gyula Poór & Piotr Wiland & Martina Olejárová & Marek Brzosko & Catalin Codreanu & Nóra Brodszky & László Gulácsi, 2014. "Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 35-43, May.
    4. Nicholas Latimer & Christopher Carroll & Ruth Wong & Paul Tappenden & Michael Venning & Raashid Luqmani, 2014. "Rituximab in Combination with Corticosteroids for the Treatment of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 32(12), pages 1171-1183, December.
    5. Lesley Uttley & Ben Kearns & Shijie Ren & Matt Stevenson, 2013. "Aripiprazole for the Treatment and Prevention of Acute Manic and Mixed Episodes in Bipolar I Disorder in Children and Adolescents: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(11), pages 981-990, November.
    6. Peter Gaal & Nóra Stefka & Júlia Nagy, 2006. "Cost accounting methodologies in price setting of acute inpatient services in Hungary," Health Care Management Science, Springer, vol. 9(3), pages 243-250, August.
    7. Imre Boncz & Valentin Brodszky & Márta Péntek & István Ágoston & Zsolt Nagy & Krisztián Kárpáti & Ildikó Kriszbacher & Péter Fuszek & László Gulácsi, 2010. "The disease burden of colorectal cancer in Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 10(1), pages 35-40, January.
    8. Katalin Gulyas & Nora Bodnar & Zsofia Nagy & Szilvia Szamosi & Agnes Horvath & Andrea Vancsa & Edit Vegh & Zoltan Szabo & Gabriella Szucs & Zoltan Szekanecz & Sandor Szanto, 2014. "Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 93-100, May.
    9. Böhm, Katharina & Schmid, Achim & Götze, Ralf & Landwehr, Claudia & Rothgang, Heinz, 2012. "Classifying OECD healthcare systems: A deductive approach," TranState Working Papers 165, University of Bremen, Collaborative Research Center 597: Transformations of the State.
    10. Mary Kilonzo & Jenni Hislop & Andrew Elders & Cynthia Fraser & Donald Bissett & Samuel McClinton & Graham Mowatt & Luke Vale, 2013. "Pazopanib for the First-Line Treatment of Patients with Advanced and/or Metastatic Renal Cell Carcinoma," PharmacoEconomics, Springer, vol. 31(1), pages 15-24, January.
    11. L. Gulácsi & M. Péntek, 2014. "HTA in Central and Eastern European countries; the 2001: A Space Odyssey and efficiency gain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(7), pages 675-680, September.
    12. Jane Burch & Susan Griffin & Claire McKenna & Simon Walker & James Paton & Kath Wright & Nerys Woolacott, 2012. "Omalizumab for the Treatment of Severe Persistent Allergic Asthma in Children Aged 6–11 Years," PharmacoEconomics, Springer, vol. 30(11), pages 991-1004, November.
    13. Petra Baji & Milena Pavlova & László Gulácsi & Miklós Farkas & Wim Groot, 2014. "The link between past informal payments and willingness of the Hungarian population to pay formal fees for health care services: results from a contingent valuation study," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(8), pages 853-867, November.
    14. Mandel Michael & Anita Bálint & Barbara Lovász & László Gulácsi & Bálint Strbák & Petra Golovics & Klaudia Farkas & Zsuzsanna Kürti & Blanka Szilágyi & Anna Mohás & Tamás Molnár & Péter Lakatos, 2014. "Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 121-128, May.
    15. E. Simpson & P. Fitzgerald & P. Evans & P. Tappenden & N. Kalita & J. Reckless & A. Bakhai, 2013. "Bivalirudin for the Treatment of ST-Segment Elevation Myocardial Infarction: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(4), pages 269-275, April.
    16. Katalin Gulyas & Nora Bodnar & Zsofia Nagy & Szilvia Szamosi & Agnes Horvath & Andrea Vancsa & Edit Vegh & Zoltan Szabo & Gabriella Szucs & Zoltan Szekanecz & Sandor Szanto, 2014. "Real-life experience with switching TNF-α inhibitors in ankylosing spondylitis," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 93-100, May.
    17. Karen Smith & Su Golder & Abeed Sarker & Yoon Loke & Karen O’Connor & Graciela Gonzalez-Hernandez, 2018. "Methods to Compare Adverse Events in Twitter to FAERS, Drug Information Databases, and Systematic Reviews: Proof of Concept with Adalimumab," Drug Safety, Springer, vol. 41(12), pages 1397-1410, December.
    18. Imre Boncz & Réka Vajda & István Ágoston & Dóra Endrei & Andor Sebestyén, 2014. "Changes in the health status of the population of Central and Eastern European countries between 1990 and 2010," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 137-141, May.
    19. Nigel Armstrong & Manuela Joore & Thea Asselt & Kate Misso & Nathan Manning & Florian Tomini & Jos Kleijnen & Rob Riemsma, 2013. "Golimumab for the Treatment of Ankylosing Spondylitis: A NICE Single Technology Appraisal," PharmacoEconomics, Springer, vol. 31(5), pages 415-425, May.
    20. Janette Greenhalgh & Adrian Bagust & Angela Boland & Michaela Blundell & James Oyee & Sophie Beale & Yenal Dundar & Juliet Hockenhull & Chris Proudlove & Patrick Chu, 2013. "Rituximab for the First-Line Maintenance Treatment of Follicular Non-Hodgkin’s Lymphoma," PharmacoEconomics, Springer, vol. 31(5), pages 403-413, May.

    More about this item

    Keywords

    Cost-utility; Inflammatory conditions; Biologicals; Central and Eastern Europe; HTA; Reimbursement;
    All these keywords.

    JEL classification:

    • I - Health, Education, and Welfare
    • I - Health, Education, and Welfare

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0591-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.